BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Paradigms Foundation - ECPv6.18.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://paradigms.foundation
X-WR-CALDESC:Events for Paradigms Foundation
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20271031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20260429T173000
DTEND;TZID=Europe/Paris:20260429T183000
DTSTAMP:20260413T155125Z
CREATED:20260413T084357Z
LAST-MODIFIED:20260413T155125Z
UID:13900-1777483800-1777487400@paradigms.foundation
SUMMARY:Live Webinar on the long-term efficacy and safety of anti-CD20 therapies
DESCRIPTION:Anti-CD20 therapies have become a central component in the management of Multiple Sclerosis (MS)\, with growing evidence supporting their sustained use. In this live webinar\, Celia Oreja-Guevara and Patrick Vermersch will review long-term efficacy and safety data\, translating current evidence into practical insights for neurologists involved in treatment decisions. \n\n\n\n \n\n\n\nKey Highlights\n\n\n\n\nReview long-term efficacy data of anti-CD20 therapies in Multiple Sclerosis (MS) \n\n\n\nAssess safety profiles with extended treatment exposure \n\n\n\nDiscuss risk–benefit considerations in long-term disease management \n\n\n\nExplore real-world evidence and its implications for clinical practice \n\n\n\nAddress monitoring strategies and patient selection over time \n\n\n\nGain expert perspectives on optimizing treatment decisions\n\n\n\n\nRegister to access the webinar\n\n\n\nThis session will be held live on Zoom. We warmly encourage you to register in advance to secure your place and take part in the exchange of knowledge and discussions. \n\n\n\n\nRegister to access the webinar\n\n\n\n\nLanguage\n\n\n\nThe session will be held in English with translated auto-captions into many languages\, offered by Zoom platform. \n\n\n\nThis webinar might interest you if you are:\n\n\n\n\nNeurologists with a particular interest in multiple sclerosis therapies and treatments\n\n\n\nNeurologists in training\n\n\n\nNurses engaged in the care of patients with multiple sclerosis\n\n\n\nPatient representatives\n\n\n\n\nQuestions and discussion\n\n\n\nIf there are specific questions you would like to see addressed during the session\, we encourage you to share them in advance at learning@paradigms.foundation. This will allow the speakers to incorporate them into their presentations. \n\n\n\nYou will also have the opportunity to raise questions directly and actively contribute to the discussion during the webinar and the dedicated Q&A session. \n\n\n\nTechnology used\n\n\n\nThe session will be conducted via Zoom\, with access credentials shared upon completion of your registration. \n\n\n\nTime and date\n\n\n\nThe session will be held in English on Wednesday\, 29 April 2026 from 5:30 to 6:30 p.m. CET. \n\n\n\nInvited Speakers\n\n\n\n\n\n\n\nCelia Oreja-Guevara\n\n\n\nVice Chair of Neurology and Head of Multiple Sclerosis Center at the University Hospital San Carlos\, Madrid \n\n\n\nAfter receiving her MD from the University Complutense\, Madrid\, Professor Oreja-Guevara completed a PhD in neuroimmunology at the Max-Planck-Institute for Neurobiology\, University of Munich\, Munich (Germany). She then went on to complete a residency in the Department of Neurology at the University of Bochum\, Bochum (Germany) and a postdoctoral fellowship in neuroimaging at the University Hospital San Raffaele\, Milan (Italy). She has also held posts at the University of Düsseldorf (Germany)\,Hospital de Fuenlabrada and at the University Hospital La Paz\, both in Madrid. \n\n\n\nProfessor Oreja-Guevara’s research interests centre on family planning\, menopause\, clinical and neuroimaging correlations in MS and the use of optical coherence tomography. As an investigator\, she has participated in a number of MS clinical trials and currently heads Paradigms\, an independent and non-profit international group of Multiple Sclerosis experts. Currently\, Professor Oreja-Guevara is an expert for the Spanish Medicines Agency and for the Scientific Advisory Group on Neurology of the European Medicines Agency. \n\n\n\n\n\n\n\nPatrick Vermersch\n\n\n\nVice-president of Research in the fields of Life and Health Sciences at the University of Lille \n\n\n\nPatrick Vermersch studied medicine at Lille University Hospital (France)\, where he graduated in Neurology. Between 1990 and 1994 he pursued his training in basic research fields\, mainly in cellular biology\, obtaining a PhD addressing biochemical abnormalities associated with Alzheimer’s and other neurodegenerative diseases. He also conducted research related to the characterization of post-transcriptional anomalies of tau proteins. His research interests then turned to multiple sclerosis (MS). \n\n\n\nProf. Patrick Vermersch is head of one of the University of Lille’s departments of Neurology which deals with MS and other neuroinflammatory diseases. The department is primarily concerned with neuroimmunology and markers of disease evolution. \n\n\n\nProf. Patrick Vermersch is currently vice-president of research in the fields of Life and Health Sciences at the University of Lille. In 2000\, he and colleagues created the first MS network in northern France to improve MS care and research. His current areas of interest are prognostic markers in MS and neuroimmunology in general. He participates in many treatment protocols for MS. He has authored or co-authored approximately 380 scientific papers. His H-index (Web of Science) is 54. \n\n\n\nFunding\n\n\n\nThis webinar is organized with the financial support of Neuraxpharm.  \n\n\n\nNeuraxpharm has not been involved in the elaboration of the presentations.
URL:https://paradigms.foundation/event/live-webinar-on-the-long-term-efficacy-and-safety-of-anti-cd20-therapies/
ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2026/04/LAU-PROD-banner-live-webinar-sessions-260429-1200x627px.jpg
END:VEVENT
END:VCALENDAR